Kong, W., Wu, G., Xu, Y., Wang, Z., Zhang, J. (2025). Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.443